Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-Pen versus GlucaGen HypoKit for rescue of induced hypoglycemia in adults with type 1 diabetes
2018-002661-19Phase 3Completed
- Sponsor
- Xeris Biopharma Holdings, Inc.
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of benzylpenicillin and glucagon in hypoglycaemia (2 arms), sponsored by Xeris Biopharma Holdings, Inc. Primary endpoint: Primary efficacy endpoint. Started Sep 2018; status: completed.
02
Drugs
benzylpenicillinglucagon
03
Conditions
hypoglycaemia
Beyond the preview
Go deeper on 2018-002661-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002661-19.